In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Danaher Corp.

www.danaher.com

Latest From Danaher Corp.

Challenges And Opportunities At The New Cytiva

In 2019, more than 75% of the biological therapies approved by the FDA used technologies developed by GE Healthcare Life Sciences for manufacturing. Following the completion of a $21.9bn acquisition by Danaher, the company has rebranded to Cytiva. In Vivo speaks with CEO Emmanuel Ligner to learn more about his vision for the new company and the impact of COVID-19. 

Business Strategies C-Suite Speaks

Cepheid Nabs First FDA Authorization For Rapid-Response COVID-19 Test

A rapid-response test from Danaher business unit Cepheid will be the first quick COVID-19 diagnostic to reach the US market, the US FDA announced on 21 March.

Coronavirus COVID-19 FDA

Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell

Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.

M & A Regenerative Medicine

Companies Deepen Therapeutic Focus: The EY Firepower Report

Growth gaps and a desire to concentrate on a small number of therapeutic areas are expected to continue to drive M&A in 2020, but thought needs to be given to investing in data-driven and digital technologies, a new EY report says.

Deals M & A
See All

Company Information

UsernamePublicRestriction

Register